FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549	
---------------	------------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CH
obligations may continue. See	
Instruction 1(b).	Filed nursuant to Se

HANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* WINSTON ROY					2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]										neck all app Direc	rector fficer (give title		10% Ov	wner
(Last) C/O PAC	(Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/03/2022									Chief Medical Officer				
5401 WI 890	EST KENN	EDY BOULEVA	ARD, SUI	ITE	4. If <i>A</i>	Amend	ment,	Date of	f Origina	al Filed	d (Month/Da	y/Yea	ır)			r Joint/Grou	p Filin	ng (Check A	pplicable
(Street) TAMPA	FL		3609										Lin	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta		Zip) I - Non-	Deriva	tive S	Secu	rities	Aca	uired.	Dis	posed of	or	Bene	eficia	ally Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				ction 2A. I Exec ay/Year) if an		A. Deemed recution Date,		3. 4. Securi Transaction Disposed Code (Instr. 5)		4. Securitie	es Acc	quired	(A) or	5. Amo	unt of ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A (D) or)	Price	Transa	ransaction(s) nstr. 3 and 4)			(1130.4)
Common Stock 08/03/2					/2022				S		476(1)		D	\$55.	5.7 44,992 ⁽²⁾			D	
		Tal									osed of, convertib					d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		,	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nur of	nber					

Explanation of Responses:

- 1. Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
- 2. Includes 408 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022.

Remarks:

/s/ Kristen Williams, Attorney-in-Fact

08/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.